Adial Pharmaceuticals Inc. Stock News

Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onw

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET

Adial Pharmaceuticals, Inc. (ADIL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ag

Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.

Adial Pharmaceuticals (ADIL) will sell 4.2M shares to a single institutional investor worth ~$10M in a registered direct offering and issue warrants in a concurrent private…

CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company") , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model. PNV-5032 Relevant Information Greater than 1000-fold selective over the adenosine A1 receptor in potency assays Demonstrated solubility more than 100 times greater than other selective adenosine compounds of the same class currently known to the Company Solubility of an inhaled product allows dissolution in the aerosolized mist for fine distribution over the bronchioles and can be important in facilitating bronchiole membrane penetration Findings indicate drug development potential of molecules of this class, possibly to treat asthma Covered by a composition of matter patent application for patent protection through 2042 with expected statutory extension to 2047 Study Design Sheep, which respond to allergens and adenosine challenges in a manner similar to humans, were initially challenged with an aerosolized dose of Ascaris Sum allergens.

CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company) , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model.

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.

CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on deve

Adial Pharmaceuticals (NASDAQ:ADIL) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The []

CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021 (the “Offering”). The shares of common stock sold in the Offering were priced at $4.00 per share and a total of 200,000 shares (the “Shares”) were purchased in the Offering. The Offering was fully subscribed.

Zacks Investment Research lowered shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. []

Zacks Investment Research upgraded shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $3.00 price target on the stock. According to Zacks, Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the [] The post Adial Pharmaceuticals (NASDAQ:ADIL) Rating Increased to Buy at Zacks Investment Research appeared first on ETF Daily News .

Analysts expect that Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) will post earnings per share (EPS) of ($0.21) for the current quarter, according to Zacks. Zero analysts have provided estimates for Adial Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.21). Adial Pharmaceuticals reported earnings of ($0.24) per []

Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the